GT
ONC icon

Glenmede Trust’s BeOne Medicines Ltd ONC Stock Holding History

Glenmede Trust’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-113
Closed -$32K – 2306
2020
Q3 		$32K Buy
113
+43
+61% +$10.1K ﹤0.01% 1447
2020
Q2 		$13K Buy
70
+41
+141% +$6.67K ﹤0.01% 1784
2020
Q1 		$4K Hold
29
– – ﹤0.01% 2736
2019
Q4 		$4K Buy
29
+2
+7% +$332 ﹤0.01% 2736
2019
Q3 		$3K Buy
27
+16
+145% +$2.13K ﹤0.01% 2797
2019
Q2 		$1K Buy
+11
New +$1.4K ﹤0.01% 2998

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Glenmede Trust's ONC Position: Q4 2020 in Review

Glenmede Trust sold out of BeOne Medicines Ltd (ONC) in Q4 2020, closing a stake of 113 shares — an estimated $32K sold.

Glenmede Trust first reported a position in ONC in Q2 2019 and held it in 6 quarters. The position peaked at $32K in Q3 2020. 248 funds tracked by Wall St. Rank hold ONC as of Q4 2020.

  • Glenmede Trust reported no remaining BeOne Medicines Ltd position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 113 BeOne Medicines Ltd shares in Q4 2020, an estimated $32K.
  • Glenmede Trust first reported a position in BeOne Medicines Ltd in Q2 2019 and held it in 6 quarters.
  • Glenmede Trust's BeOne Medicines Ltd position peaked at $32K in Q3 2020.
  • 248 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.